135 related articles for article (PubMed ID: 15351379)
1. Physiological measures of therapeutic response to interferon beta-1a treatment in remitting-relapsing MS.
White AT; Petajan JH
Clin Neurophysiol; 2004 Oct; 115(10):2364-71. PubMed ID: 15351379
[TBL] [Abstract][Full Text] [Related]
2. Post-exercise facilitation and depression of motor evoked potentials to transcranial magnetic stimulation: a study in multiple sclerosis.
Perretti A; Balbi P; Orefice G; Trojano L; Marcantonio L; Brescia-Morra V; Ascione S; Manganelli F; Conte G; Santoro L
Clin Neurophysiol; 2004 Sep; 115(9):2128-33. PubMed ID: 15294215
[TBL] [Abstract][Full Text] [Related]
3. Prospective clinical and electrophysiological follow-up on a multiple sclerosis population treated with interferon beta-1 a: a pilot study.
Feuillet L; Pelletier J; Suchet L; Rico A; Ali Cherif A; Pouget J; Attarian S
Mult Scler; 2007 Apr; 13(3):348-56. PubMed ID: 17439904
[TBL] [Abstract][Full Text] [Related]
4. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls.
Goldman MD; Marrie RA; Cohen JA
Mult Scler; 2008 Apr; 14(3):383-90. PubMed ID: 17942508
[TBL] [Abstract][Full Text] [Related]
6. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis.
Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
Eur Neurol; 2008; 59(3-4):131-5. PubMed ID: 18057899
[TBL] [Abstract][Full Text] [Related]
7. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
8. Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
[TBL] [Abstract][Full Text] [Related]
9. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
Mezei Z; Bereczki D; Csiba L; Csépány T
Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
11. Patients with primary biliary cirrhosis do not show post-exercise depression of cortical excitability.
Cerri G; Cocchi CA; Montagna M; Zuin M; Podda M; Cavallari P; Selmi C
Clin Neurophysiol; 2010 Aug; 121(8):1321-8. PubMed ID: 20363183
[TBL] [Abstract][Full Text] [Related]
12. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
13. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
[TBL] [Abstract][Full Text] [Related]
14. Effects of low-frequency whole-body vibration on motor-evoked potentials in healthy men.
Mileva KN; Bowtell JL; Kossev AR
Exp Physiol; 2009 Jan; 94(1):103-16. PubMed ID: 18658234
[TBL] [Abstract][Full Text] [Related]
15. Fatigue perceived by multiple sclerosis patients is associated with muscle fatigue.
Steens A; de Vries A; Hemmen J; Heersema T; Heerings M; Maurits N; Zijdewind I
Neurorehabil Neural Repair; 2012 Jan; 26(1):48-57. PubMed ID: 21856990
[TBL] [Abstract][Full Text] [Related]
16. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study.
Ghezzi A;
Neurol Sci; 2005 Dec; 26 Suppl 4():S183-6. PubMed ID: 16388355
[TBL] [Abstract][Full Text] [Related]
18. Brain excitability changes in the relapsing and remitting phases of multiple sclerosis: a study with transcranial magnetic stimulation.
Caramia MD; Palmieri MG; Desiato MT; Boffa L; Galizia P; Rossini PM; Centonze D; Bernardi G
Clin Neurophysiol; 2004 Apr; 115(4):956-65. PubMed ID: 15003779
[TBL] [Abstract][Full Text] [Related]
19. Fatigued patients with multiple sclerosis have impaired central muscle activation.
Andreasen AK; Jakobsen J; Petersen T; Andersen H
Mult Scler; 2009 Jul; 15(7):818-27. PubMed ID: 19465444
[TBL] [Abstract][Full Text] [Related]
20. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.
Jung P; Beyerle A; Ziemann U
Mult Scler; 2008 May; 14(4):553-6. PubMed ID: 18562509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
